Cara Therapeutics (CARA) Misses Q1 EPS by 7c

Cara Therapeutics (NASDAQ: CARA) reported Q1 EPS of ($0.81), $0.07 worse than the analyst estimate of ($0.74). Revenue for the quarter came in at $843 thousand versus the consensus estimate of $150 thousand.

For earnings history and earnings-related data on Cara Therapeutics (CARA) click here.

You May Also Be Interested In

• Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
• Jefferies Reinstates Talen Energy (TLN) at Hold
• AeroVironment restates quarterly financials, citing $89M goodwill error